- Home
- WATT vs LIXT Comparison
WATT vs LIXT Comparison
Compare WATT & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- LIXT
- Stock Information
- Founded
- WATT 2012
- LIXT 2005
- Country
- WATT United States
- LIXT United States
- Employees
- WATT N/A
- LIXT N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- LIXT Health Care
- Exchange
- WATT Nasdaq
- LIXT Nasdaq
- Market Cap
- WATT 3.9M
- LIXT 4.2M
- IPO Year
- WATT 2014
- LIXT N/A
- Fundamental
- Price
- WATT $0.47
- LIXT $1.66
- Analyst Decision
- WATT Strong Buy
- LIXT
- Analyst Count
- WATT 2
- LIXT 0
- Target Price
- WATT $2.25
- LIXT N/A
- AVG Volume (30 Days)
- WATT 201.1K
- LIXT 1.8M
- Earning Date
- WATT 11-12-2024
- LIXT 11-12-2024
- Dividend Yield
- WATT N/A
- LIXT N/A
- EPS Growth
- WATT N/A
- LIXT N/A
- EPS
- WATT N/A
- LIXT N/A
- Revenue
- WATT $431,184.00
- LIXT N/A
- Revenue This Year
- WATT $95.75
- LIXT N/A
- Revenue Next Year
- WATT $834.07
- LIXT N/A
- P/E Ratio
- WATT N/A
- LIXT N/A
- Revenue Growth
- WATT N/A
- LIXT N/A
- 52 Week Low
- WATT $0.45
- LIXT $1.31
- 52 Week High
- WATT $2.75
- LIXT $4.42
- Technical
- Relative Strength Index (RSI)
- WATT 32.37
- LIXT 47.51
- Support Level
- WATT $0.45
- LIXT $1.45
- Resistance Level
- WATT $0.58
- LIXT $1.62
- Average True Range (ATR)
- WATT 0.04
- LIXT 0.16
- MACD
- WATT -0.01
- LIXT -0.01
- Stochastic Oscillator
- WATT 12.96
- LIXT 39.62
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.